Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 81: For a menopausal patient having hot flashes, which of the following can be given as treatment?

A. Progesterone
B. 17β-estradiol (Correct Answer)
C. Danazol
D. Gonadotropin

Explanation: ***17β-estradiol*** - **Estrogen therapy** is the **gold standard** and **most effective treatment** for menopausal vasomotor symptoms including hot flashes - **17β-estradiol** directly replaces the declining ovarian estrogen levels that cause hot flashes - Recommended by all major guidelines (NAMS, ACOG, IMS) as **first-line therapy** for moderate to severe vasomotor symptoms - Available in various formulations: oral, transdermal patches, gels, and sprays - In women with an intact uterus, progestogen must be added to prevent endometrial hyperplasia *Progesterone* - **Progestogens** (synthetic progesterone) are primarily used to **protect the endometrium** when estrogen is prescribed to women with an intact uterus - Can provide **mild relief** of hot flashes in some women, but are **significantly less effective** than estrogen therapy - May be considered as **monotherapy** only when estrogen is contraindicated (e.g., breast cancer, thromboembolic disease) - **Not first-line treatment** for vasomotor symptoms *Danazol* - An **attenuated androgen** with anti-estrogenic and androgenic properties - Used primarily for **endometriosis** and **fibrocystic breast disease** - Would **worsen menopausal symptoms** including hot flashes due to its anti-estrogenic effects - Contraindicated in menopause management *Gonadotropin* - **FSH and LH** levels are already **markedly elevated** in menopause due to lack of negative feedback from ovarian hormones - Used in **fertility treatment**, not menopausal symptom management - Exogenous gonadotropin administration is **inappropriate and ineffective** for hot flashes

Question 82: In menopause, which of the following is seen:

A. High FSH (Correct Answer)
B. High progesterone
C. High estrogen
D. Low FSH

Explanation: ***High FSH*** - In **menopause**, the ovaries lose their ability to produce **estrogen** and **progesterone**, leading to a decline in their levels. - This decline in ovarian hormones removes the **negative feedback** on the **hypothalamus** and **anterior pituitary**, causing a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, **follicle-stimulating hormone (FSH)**, and **luteinizing hormone (LH)**. *High progesterone* - **Progesterone** levels are typically **low** in menopause because the ovaries are no longer ovulating or producing the corpus luteum, which is the primary source of progesterone. - While progesterone is important in the normal menstrual cycle, its production ceases after the final menstrual period. *High estrogen* - **Estrogen** levels are generally **low** in menopause due to the cessation of ovarian follicular activity. - The decline in estrogen is responsible for many menopausal symptoms, such as hot flashes and vaginal dryness. *Low FSH* - **Low FSH** is typically seen in conditions where there is sufficient **estrogen** and **progesterone** exerting negative feedback on the pituitary, or in primary pituitary/hypothalamic dysfunction. - In menopause, the **lack of ovarian hormones** specifically causes FSH (and LH) levels to be significantly elevated.

Question 83: Earliest menopausal symptom is :

A. Vaginal discharge
B. Osteoporosis
C. Hot flushes (Correct Answer)
D. Spotting

Explanation: ***Hot flushes*** - **Hot flushes** are the **earliest and most common vasomotor symptom** experienced by women during perimenopause due to fluctuating estrogen levels. - They are often the first **symptomatic complaint** that brings women to clinical attention and can begin several years before the final menstrual period. - While menstrual irregularities occur concurrently, hot flushes are considered the hallmark **early symptom** of menopausal transition. *Vaginal discharge* - **Vaginal discharge** can occur due to various reasons, including infections or hormonal changes, but it is not typically the earliest or a universal symptom of menopause. - While vaginal dryness and atrophy are common menopausal symptoms, increased discharge is not characteristic of early menopause. *Osteoporosis* - **Osteoporosis** is a long-term consequence of estrogen deficiency that develops **years after menopause**, leading to decreased bone density. - It is not an early symptom but rather a chronic condition that manifests significantly later in the postmenopausal period. *Spotting* - **Spotting** (intermenstrual bleeding) can be a sign of perimenopause as menstrual cycles become irregular. - While **menstrual irregularity** is an early feature of perimenopause, hot flushes are more consistently recognized as the **earliest symptomatic presentation** that characterizes the menopausal transition.

Question 84: All of the following statements about HRT (hormone replacement therapy) are true except:

A. It increases the risk of coronary artery disease
B. It increases bone mineral density
C. It increases the risk of breast cancer
D. It increases the risk of endometrial cancer (Correct Answer)

Explanation: ***It increases the risk of endometrial cancer*** - This statement is only true for **unopposed estrogen** therapy in women with an intact uterus; combined HRT (estrogen plus progesterone) significantly **reduces** this risk. - The addition of **progesterone** to estrogen HRT is protective against endometrial hyperplasia and cancer. *It increases the risk of coronary artery disease* - Studies have shown that HRT, particularly when initiated several years after menopause, can **increase the risk of cardiovascular events**, including coronary artery disease. - The **Women's Health Initiative (WHI)** study highlighted these risks, especially in older women starting HRT. *It increases bone mineral density* - Estrogen is crucial for maintaining bone density, and HRT can **slow down bone loss** and **reduce the risk of osteoporosis and fractures** in postmenopausal women. - This is a well-established benefit of HRT for bone health. *It increases the risk of breast cancer* - Combined estrogen-progestin HRT has been consistently shown to **increase the risk of breast cancer**, especially with prolonged use (more than 3-5 years). - This increased risk is a significant concern when considering HRT.

Question 85: All of the following are true about hot flushes EXCEPT:

A. Possible role of serotonin is implicated
B. Can start several years before menopause
C. Can persist for several years after menopause
D. Can affect the entire body, not just specific regions (Correct Answer)

Explanation: ***Can affect the entire body, not just specific regions*** - While hot flashes are experienced as a **systemic sensation of heat**, they are predominantly characterized by intense warmth in the **upper body**, head, and neck, along with sweating, flushing, and palpitations. - The sensation of warmth is usually perceived to emanate from the chest or neck, spreading upwards, rather than encompassing the entire body uniformly. *Possible role of serotonin is implicated* - The **pathophysiology of hot flashes** is complex and involves neurotransmitter systems, with **serotonin** (5-HT) pathways in the brain playing a significant role in thermoregulation. - Drugs that modulate serotonin, such as **selective serotonin reuptake inhibitors (SSRIs)**, have been shown to reduce the frequency and severity of hot flashes. *Can start several years before menopause* - **Vasomotor symptoms**, including hot flashes, often begin during the **perimenopause**, which is the transitional period leading up to menopause. - This phase typically starts several years before the final menstrual period, when **hormonal fluctuations**, particularly in estrogen levels, become more pronounced. *Can persist for several years after menopause* - For many women, hot flashes can continue for an extended period into the **postmenopausal years**. - Studies indicate that the duration of hot flashes can vary widely, with some women experiencing them for **more than 10 years** after their final menstrual period.

Question 86: Which of the following is an indication for use of Hormone Replacement Therapy in menopausal women:-

A. Post menopausal bleeding
B. Hot flushes (Correct Answer)
C. Cardiovascular protection
D. Pyelonephritis

Explanation: ***Hot flushes*** - Hormone Replacement Therapy (HRT) is highly effective in alleviating **vasomotor symptoms** like hot flushes and night sweats, which can severely impact quality of life in menopausal women. - The primary goal of using HRT is to manage these **menopausal symptoms** when they are bothersome. *Post menopausal bleeding* - **Postmenopausal bleeding** is a contraindication, not an indication, for new HRT initiation as it requires investigation to rule out endometrial pathology, including cancer. - If a woman on HRT experiences bleeding, it warrants immediate investigation to determine its cause and may necessitate stopping or changing the HRT regimen. *Cardiovascular protection* - While earlier beliefs suggested HRT offered cardiovascular protection, current evidence, particularly from the **Women's Health Initiative (WHI) study**, showed that HRT does not provide primary or secondary cardiovascular protection. - In fact, HRT may increase the risk of **cardiovascular events** like stroke and venous thromboembolism, especially when initiated many years after menopause. *Pyelonephritis* - **Pyelonephritis** is an infection of the kidney, typically caused by bacteria, and is not directly related to menopausal symptoms or hormonal status. - Treatment for pyelonephritis involves **antibiotics** and supportive care, not HRT.

Question 87: A woman with postmenopausal bleeding has thickened endometrium. Which approach is most suitable for evaluating malignancy risk?

A. Endometrial biopsy (Correct Answer)
B. Transvaginal ultrasound
C. Pap smear
D. Hysteroscopy

Explanation: ***Endometrial biopsy*** - An **endometrial biopsy** directly obtains tissue samples from the endometrial lining, allowing for histological examination to definitively diagnose or rule out **endometrial hyperplasia** or **carcinoma**. - This is the **most suitable first-line approach** when postmenopausal bleeding is coupled with a thickened endometrium, as it directly assesses for **malignancy at a cellular level**. - It is **cost-effective, minimally invasive, and can be performed in an office setting** without anesthesia. *Transvaginal ultrasound* - While a **transvaginal ultrasound** can measure endometrial thickness and identify structural abnormalities, it cannot definitively differentiate between benign and malignant changes. - It serves as an initial screening tool but requires further investigation like a **biopsy** for definitive diagnosis in cases of thickened endometrium and postmenopausal bleeding. - An endometrial thickness >4-5 mm in postmenopausal women warrants tissue diagnosis. *Pap smear* - A **Pap smear** (Papanicolaou test) is used to screen for **cervical cancer** by collecting cells from the cervix. - It is not effective for detecting **endometrial pathologies** or cancer of the uterine lining. *Hysteroscopy* - **Hysteroscopy** allows for direct visualization of the uterine cavity and directed biopsies under direct vision, which is highly accurate for identifying focal lesions such as polyps or fibroids. - While it provides excellent diagnostic accuracy, it is **more invasive, expensive, and typically requires anesthesia**. - For initial evaluation of postmenopausal bleeding with diffuse endometrial thickening, **endometrial biopsy is preferred** as the first-line approach due to its accessibility, lower cost, and adequate sensitivity (>90% for detecting endometrial cancer).

Question 88: What is the endometrial thickness threshold on ultrasound that warrants further investigation in postmenopausal bleeding?

A. <3 mm
B. 5-10 mm
C. >4 mm (Correct Answer)
D. >20 mm

Explanation: ***>4 mm*** - An endometrial thickness of **greater than 4 mm** in a postmenopausal woman with bleeding is the standard threshold that warrants further investigation for potential **endometrial hyperplasia** or **endometrial cancer**. - This cutoff is recommended by major international guidelines (ACOG, RCOG) and has approximately **90-96% sensitivity** for detecting endometrial cancer. - Findings exceeding this threshold typically prompt **endometrial biopsy** or **hysteroscopy** to rule out malignancy. *<3 mm* - An endometrial thickness of **less than 3 mm** in a postmenopausal woman with bleeding is generally considered **reassuring**, with a very low risk (<1%) of endometrial malignancy. - No further invasive evaluation (e.g., biopsy) is typically required below this threshold. *5-10 mm* - While **5-10 mm** is indeed concerning and would require investigation, it represents a range **above** the initial threshold rather than the threshold itself. - The question asks for the **cutoff value** that triggers investigation, which is **>4 mm**, not a range above that cutoff. *>20 mm* - An endometrial thickness **>20 mm** is highly concerning and indicates significant pathology such as **advanced hyperplasia** or **carcinoma**. - However, the initial **threshold for investigation** is **>4 mm**, making this an unnecessarily high cutoff that would miss many cases requiring evaluation.

Question 89: A 45-year-old woman with irregular menses and hot flashes has a serum FSH level of 40 IU/L. What is the most likely diagnosis?

A. Perimenopause (Correct Answer)
B. Pregnancy
C. Hypothyroidism
D. Pituitary adenoma

Explanation: ***Perimenopause*** - **Irregular menses**, **hot flashes**, and an **elevated FSH level (40 IU/L)** are classic symptoms and laboratory findings indicative of **perimenopause**. - During perimenopause, ovarian function declines, leading to decreased estrogen production and a compensatory rise in **FSH**. *Pregnancy* - Pregnancy would typically result in **amenorrhea** and specific hormonal changes such as elevated **hCG**, not an elevated FSH. - While irregular menses might precede pregnancy in some cases, the described symptoms and high FSH are not consistent with pregnancy itself. *Hypothyroidism* - Hypothyroidism can cause menstrual irregularities and fatigue, but **hot flashes** are not a typical symptom. - It would be associated with elevated **TSH** and low **thyroid hormones**, not primarily elevated FSH. *Pituitary adenoma* - A pituitary adenoma could cause menstrual irregularities and headaches or visual disturbances, depending on its size and hormone secretion (e.g., **prolactinoma**). - However, an isolated elevated FSH without other pituitary hormone abnormalities or masses on imaging is not characteristic of a pituitary adenoma.

Question 90: What is the first-line pharmacological treatment for managing menopausal symptoms in women without a uterus?

A. Estrogen-only therapy (Correct Answer)
B. Combined estrogen-progestin therapy
C. Selective estrogen receptor modulators
D. Non-hormonal therapies

Explanation: ***Estrogen-only therapy*** - In women without a uterus (**hysterectomy**), **estrogen-only therapy** is the first-line treatment for menopausal symptoms because there is no risk of **endometrial hyperplasia** or **endometrial cancer**. - **Estrogen** effectively treats common symptoms like **hot flashes** and **vaginal dryness**. *Combined estrogen-progestin therapy* - This therapy is indicated for women with an intact uterus to protect the **endometrium** from **estrogen-induced hyperplasia** and **cancer**. - Prescribing **progestin** to a woman without a uterus offers no additional benefit and adds potential side effects. *Selective estrogen receptor modulators* - **SERMs** (e.g., **raloxifene**, **tamoxifen**) have mixed agonist/antagonist effects on **estrogen** receptors in different tissues. - While they can be used for specific conditions like **osteoporosis** or **breast cancer prevention**, they are not typically considered first-line for overall menopausal symptom management due to their varied effects and potential side effects compared to **estrogen** therapy for general menopausal symptoms. *Non-hormonal therapies* - These include **SSRIs**, **SNRIs**, **gabapentin**, and **clonidine**, which are considered for women with contraindications to **hormone therapy** or those who prefer non-hormonal options. - While effective for some symptoms, they are generally not as potent as **estrogen** for **vasomotor symptoms** and are typically considered second-line or alternative treatments.

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?